Advertisement
Advertisement
October 2, 2025
Abbott’s Esprit BTK Everolimus-Eluting Resorbable Scaffold System Approved in Canada
October 2, 2025—Abbott announced that Health Canada has authorized the Esprit BTK everolimus-eluting resorbable scaffold system for the treatment of patients with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).
The company stated that the Esprit BTK system is a dissolvable stent that opens the blockage, then helps heal the vessel and provides support for approximately 3 years until the vessel is strong enough to remain open on its own.
According to Abbott, the 2-year findings from the LIFE-BTK trial demonstrated that compared to balloon angioplasty, the Esprit BTK system resulted in improved patient outcomes and 48% fewer repeat procedures over the study period. In November 2024, Brian DeRubertis, MD, presented the findings at VIVA24, the Vascular InterVentional Advances annual symposium.
“Health Canada’s approval of Abbott’s Esprit BTK system marks a significant milestone in our fight against peripheral artery disease below-the-knee and represents a new era of improved outcomes for people worldwide,” commented Dr. DeRubertis in the company’s press release. “Abbott is changing the landscape of CLTI therapy by introducing a treatment option that is superior to balloon angioplasty.”
Advertisement
Advertisement
